Tenax Therapeutics, Inc. Common Stock TENX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T02:01:56.868Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T00:45:18.554726076Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-13T02:01:56.436988+00:00
Tenax Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 3.48 | 610.4% | 125.8% | 1.52 | 231.1% | 17.1% |
| 40Δ | 3.16 | 552.1% | 107.4% | 1.58 | 221.8% | 15.4% |
| 45Δ | 2.85 | 493.8% | 89.1% | 1.63 | 212.5% | 13.7% |
| 50Δ | 2.54 | 435.5% | 70.8% | 1.69 | 203.2% | 12.0% |
| 55Δ | 2.23 | 377.3% | 52.5% | 1.74 | 193.9% | 10.3% |
| 60Δ | 1.92 | 319.0% | 34.2% | 1.80 | 184.6% | 8.6% |
| 65Δ | 1.60 | 260.7% | 15.9% | 1.86 | 175.2% | 6.9% |
| 70Δ | 1.43 | 248.6% | 8.7% | 1.91 | 165.9% | 5.2% |
| 75Δ | 1.33 | 259.6% | 7.2% | 1.97 | 156.6% | 3.5% |
| 80Δ | 1.23 | 270.7% | 5.6% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 3.48
- IV
- 610.4%
- B/E move
- 125.8%
- Pseudo strike
- 1.52
- IV
- 231.1%
- B/E move
- 17.1%
40Δ
- Pseudo strike
- 3.16
- IV
- 552.1%
- B/E move
- 107.4%
- Pseudo strike
- 1.58
- IV
- 221.8%
- B/E move
- 15.4%
45Δ
- Pseudo strike
- 2.85
- IV
- 493.8%
- B/E move
- 89.1%
- Pseudo strike
- 1.63
- IV
- 212.5%
- B/E move
- 13.7%
50Δ
- Pseudo strike
- 2.54
- IV
- 435.5%
- B/E move
- 70.8%
- Pseudo strike
- 1.69
- IV
- 203.2%
- B/E move
- 12.0%
55Δ
- Pseudo strike
- 2.23
- IV
- 377.3%
- B/E move
- 52.5%
- Pseudo strike
- 1.74
- IV
- 193.9%
- B/E move
- 10.3%
60Δ
- Pseudo strike
- 1.92
- IV
- 319.0%
- B/E move
- 34.2%
- Pseudo strike
- 1.80
- IV
- 184.6%
- B/E move
- 8.6%
65Δ
- Pseudo strike
- 1.60
- IV
- 260.7%
- B/E move
- 15.9%
- Pseudo strike
- 1.86
- IV
- 175.2%
- B/E move
- 6.9%
70Δ
- Pseudo strike
- 1.43
- IV
- 248.6%
- B/E move
- 8.7%
- Pseudo strike
- 1.91
- IV
- 165.9%
- B/E move
- 5.2%
75Δ
- Pseudo strike
- 1.33
- IV
- 259.6%
- B/E move
- 7.2%
- Pseudo strike
- 1.97
- IV
- 156.6%
- B/E move
- 3.5%
80Δ
- Pseudo strike
- 1.23
- IV
- 270.7%
- B/E move
- 5.6%
- Pseudo strike
- IV
- B/E move
Options history
Table
| Date | IV (%) |
|---|---|
| 183.32% | |
| 127.64% | |
| 233.01% | |
| 140.95% | |
| 201.83% | |
| 237.68% | |
| 178.12% | |
| 185.67% | |
| 137.95% | |
| 166.85% |
Biotechnology
TGTX
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and…
More →TNGX
Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation, specializing in synthetic lethality and targeted therapies.…
More →TNXP
Tonix Pharmaceuticals Holding Corp. The company is headquartered in Chatham, New Jersey.
More →TNYA
Tenaya Therapeutics Inc. is a pioneering clinical-stage biotechnology firm that is revolutionizing the treatment of heart disease through its proprietary engineered heart cell…
More →TRAX
First Tracks Biotherapeutics (Ticker: TRAX) is a forward-thinking biotechnology company focused on developing targeted therapeutics for chronic diseases, utilizing advanced…
More →TRDA
Entrada Therapeutics Inc. (TRDA) is a forward-thinking biotechnology company focused on creating innovative therapies for severe diseases characterized by significant unmet…
More →